Recently, Murano et al. reported that SBRT in oligometastatic breast cancer patients resulted in an increase or even new appearance of polyfunctional CD4+ and CD8+ T-cells against breast cancer antigens (34). This evidence concerns the gene CD4 and breast carcinoma.